Conference Coverage

VIDEO: Let clinical scenario, not imaging, guide sarcoidosis treatment


 

REPORTING FROM CCR 18


For patients who fall onto the “treat” side of the risk teeter-totter, Dr. Culver recommended starting with an initial course of prednisone at 20-30 mg daily for no more than 4 weeks. Responders can taper to less than 10 mg/day. Those who continue to do well can maintain low-dose prednisone for up to 12 months and then complete the taper. Patients who relapse can add an immune modulator (methotrexate, azathioprine, leflunomide, or mycophenolate).

Those who have an inadequate response to the initial prednisone course should then get an immune modulator. If they do well, that can be maintained; a second modulator can be brought on board if necessary.

For those who don’t respond at all to the initial prednisone course, it’s necessary to proceed immediately to an immunosuppressive regimen to prevent irreversible fibrosis.

Dr. Culver noted associations with multiple pharmaceutical companies, but said none were relevant to his talk.

SOURCE: Culver D. CCR 2018.

Pages

Recommended Reading

SLE: Specialized lupus clinics may offer superior quality of care
MDedge Rheumatology
Patient perspective improves dry eye syndrome research
MDedge Rheumatology
Infections predispose patients to developing Sjögren’s
MDedge Rheumatology
Self-administration of subcutaneous belimumab could eliminate hospital visits for SLE patients
MDedge Rheumatology
Lupus is quietly killing young women
MDedge Rheumatology
MDedge Daily News: Which nonopioids are ripe for abuse?
MDedge Rheumatology
MDedge Daily News: Lupus is quietly killing young women
MDedge Rheumatology
Heart disease in GPA exacts high toll in year 2 and beyond
MDedge Rheumatology
Even a year of increased water intake did not change CKD course
MDedge Rheumatology
VIDEO: Dual studies seek answers in isolated skin vasculitis
MDedge Rheumatology